01 Growing Adoption of Radial-First Approaches in Cardiovascular Interventions The market is shifting toward radial artery access as clinicians increasingly use the wrist-based approach for coronary and peripheral vascular procedures. Compared with femoral access, transradial procedures can reduce bleeding and vascular complications while supporting earlier patient ambulation and discharge. This broader clinical adoption increases demand for radial access kits, introducer sheaths, guidewires, and related access products. In December 2024, the American Heart Association published a scientific statement describing the expanding role of transradial access in peripheral vascular interventions and its application across neurovascular, renal, mesenteric, uterine, and lower-extremity procedures.
02 Increasing Focus on Patent Hemostasis and Radial Artery Preservation Transradial access technology is increasingly emphasizing controlled post-procedure compression that achieves hemostasis while maintaining radial artery patency. This is encouraging development and adoption of dedicated compression devices with adjustable pressure and monitoring features, as radial artery occlusion remains an important access-related complication. In July 2026, the U.S. FDA device database listed the Arrow TransRadial Arterial Access Device and TransRadial Artery Access Kit as Class II cardiovascular introducer devices, reflecting continued availability of dedicated radial-access products.
01 Expansion of Transradial Coronary and Peripheral Procedures Increases Device Demand The growing use of transradial access across coronary and peripheral interventions is increasing requirements for specialized access devices. Clinicians use radial access because it can reduce bleeding and vascular complications and enable faster post-procedure recovery compared with femoral access. As radial-first strategies expand into additional vascular procedures, demand for dedicated access kits and supporting devices increases.
01 Operator Training and Technical Requirements Limit Consistent Transradial Adoption Transradial procedures require appropriate patient selection, access-site assessment, specialized technique, and operator proficiency. Radial artery spasm, anatomical variation, and radial artery occlusion can complicate procedures and require clinicians to maintain specific skills. These technical requirements can slow adoption in facilities where experience with radial access remains limited.
01 Expansion of Radial Access Into Peripheral Interventions Creates New Device Applications The increasing use of radial access for peripheral and noncoronary interventions creates opportunities for longer access devices, specialized sheaths, guidewires, and procedure-specific kits. As clinicians use the radial route for interventions involving vessels beyond the coronary circulation, manufacturers can develop devices suited to greater procedural reach and different anatomical requirements.
01 Preventing Radial Artery Occlusion While Achieving Effective Hemostasis Remains Difficult Device manufacturers must balance sufficient compression to control bleeding with preservation of radial artery blood flow after catheter removal. Excessive or prolonged compression can contribute to radial artery occlusion, while inadequate compression can increase bleeding risk. This creates a technical challenge for manufacturers developing compression bands and post-procedure hemostasis systems.
August 2025 Merit Medical Systems commercially launched the Prelude Wave™ Hydrophilic Sheath Introducer with SnapFix™ securement technology in the U.S., enhancing sheath stability and helping reduce arterial spasm and occlusion during transradial procedures.
February 2025 Edwards Lifesciences received CE Mark approval for an expanded indication of its SAPIEN 3 Transcatheter Valve System with a transradial delivery option, supporting less invasive cardiovascular procedures.
May 2024 Merit Medical Systems completed the acquisition of Endovascular Technologies, strengthening its portfolio of transradial access devices and expanding its presence in interventional cardiology.
March 2024 Terumo Corporation entered a strategic research collaboration with the University of California, San Francisco (UCSF) to develop next-generation transradial access technologies aimed at improving procedural outcomes.